Dr David Earl Johanknecht, OD | |
269 Memorial Dr, Suite 103, Berlin, WI 54923 | |
(920) 361-1696 | |
(920) 361-1247 |
Full Name | Dr David Earl Johanknecht |
---|---|
Gender | Male |
Speciality | Optometrist |
Location | 269 Memorial Dr, Berlin, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114078243 | NPI | - | NPPES |
38563200 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | 1404-035 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr David Earl Johanknecht, OD Po Box 228, Berlin, WI 54923-0228 Ph: (920) 361-1696 | Dr David Earl Johanknecht, OD 269 Memorial Dr, Suite 103, Berlin, WI 54923 Ph: (920) 361-1696 |
News Archive
MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Hi-Tech Pharmacal Co., Inc. announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech's branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis.
Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.
Shire plc today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
› Verified 7 days ago
Dr. Tammi L Sawallish, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 269 Memorial Dr Ste 103, Berlin, WI 54923 Phone: 920-361-1696 Fax: 920-361-1247 | |
Dr. Micheal Dean Gerber, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 269 Memorial Dr, Suite 103, Berlin, WI 54923 Phone: 920-361-1696 Fax: 920-361-1247 | |
Berlin Family Eye Care Sc Optometrist Medicare: Medicare Enrolled Practice Location: 269 Memorial Dr, Suite 103, Berlin, WI 54923 Phone: 920-361-1696 Fax: 920-361-1247 |